

# Hematological and Coagulation Features of COVID-19 Patients in Hodeidah, Yemen

*Abstract :*

**Background :** The blood parameters are very important markers for the progression of COVID-19 infection and predictor for severity.

**Objectives:** Therefore, the study aimed to describe the hematological and coagulation features of coronavirus disease 2019 (COVID-19) infection. **Methodology:** The descriptive study (a case series) included 49 patients that were diagnosed clinically and confirmed by the real time – polymerase chain reaction (RT-PCR) with COVID-19. The patients were extremely debilitated and the critical cases were treated in the isolation center (inpatient).

**Results:** The results revealed that 85.7 % of the patients had pretreatment leukocytosis with average count of WBC  $15.24 \pm 6.18 (\times 10^9/L)$ . On the other hand, the WBC count, which had reached a peak of  $34 (\times 10^9/L)$  as maximum value. Also, the reduction of the lymphocytes (lymphopenia) associated with COVID-19 infection was up to 1 % with average  $(8.75 \pm 6.92\%)$ . The neutrophils increased (neutrophilia) to 98 % with average  $(87.40 \pm 8.45\%)$ . In addition, the thrombocytopenia was reported in 2/49 cases (4.08 %), and low in hemoglobin (severe anemia) was reported in 5/49 case (10.20 %). The coagulation tests revealed increased in d-dimer levels ( $p < 0.05$ ) in severe and critical patients. On the other hand, the results showed normal in prothrombin time (PT) and partial thromboplastin (PTT) ( $p > 0.05$ ).

**Conclusion:** The study concluded that neutrophils - lymphocytes ratio is good predictor for progressive and severity illness in COVID-19 infection.

**Comment [d1]:** The NL ratio do not appear in the result section of the study. It is not a correct conclusion of this investigation.

**Keywords :** COVID-19 infection, coagulation, hematological parameters

## 1. INTRODUCTION

The hematological parameters are described as predictors for the severity and progression of COVID-19 infection. The COVID-19 disease was firstly reported in Wuhan, China, in December

2019[1]. The novel contagious disease was caused by an unfamiliar coronavirus related to the virus that caused the SARS (severe acute respiratory distress syndrome) outbreak in 2002 (SARS-CoV) and Middle East respiratory syndrome (MERS) outbreak in 2012. It should be regarded as a systemic disease involving multiple systems are involved including cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic and immune system[2]. Full blood count (FBC) is inexpensive and not difficult to perform. Included in the FBC are various values, including counts of leucocytes (neutrophils and lymphocytes) and thrombocytes, indices of erythrocytes, and certain ratios of these values. Of leucocytes, the neutrophils are the most distinctive and essential component of the immune system. The role of lymphocytes in infections is well evidenced. Moreover, thrombocytes have a crucial role in the regulation of several inflammatory processes[3,4].

**Comment [d2]:** The parts of the FBC are not relevant to the topic.

**Comment [d3]:** Citation?

The clinical hematology laboratory plays an important role by providing the clinical team a number of useful prognostic markers [4]. Although information is in some cases based on the results of limited amount of data and should be validated with additional studies, the available findings clearly establish the clinical hematology laboratory as an important partner in the triage and management of affected patients. The results of a CBC can provide information about not only the number of cell types but can also give an indication of the physical characteristics of some of the cells. Also, these parameters play an important role in helping doctors to know these values in a true way so that they can come to a sound diagnosis [5]. Therefore, the study aimed to describe the hematological features of COVID-19 infection .

**Comment [d4]:** abbreviation

## 2. METHODOLOGY

**Comment [d5]:** Based on what criteria the authors divided the two groups of severe and critical patients?

### 3.1. Study area

Center of Tropical Medicine and Infectious Diseases (CTMID), Al Thawara Public Hospital Authority, Hodeidah, Yemen from 1<sup>st</sup> June to 31<sup>st</sup> December 2020. Note : The area is endemic of vector – borne diseases (VBDs) such as the malaria , dengue and vaccine – preventable diseases (VBDs) that cause other infection (coinfection) to effect on hematological parametric [6-10].

### 3.2. Study design

This study was designed in a case series. It focuses on the patients who sought care at the emergency team, COVID-19 isolation department.

### 3.3. COVID-19 confirmation

49 severe and critical patients were confirmed and admitted in the COVID-19 isolation department, which was located at CTMID. Nasopharyngeal swabs were collected and verified by Real Time - Polymerase Chain Reaction (RT-PCR), oxygen saturation, radiological and hematological findings were tested [11-16].

### 3.4. Samples collection

Whole blood samples namely 49 (40 male and 9 female) were taken before treatment and collected into the ethylenediaminetetraacetic acid (EDTA) tube, and then sent to the clinical laboratory for analysis of standard clinical tests within two hours.

**Comment [d6]:** Add at what age (mean and range)

### 3.5. Hematological and blood coagulation assays

Hematological parameters namely RBC , WBC and Platelets were analyzed by Sysmex XE-5000 automated hematology analyzer (Sysmex, Japan). Also, coagulation tests as Prothrombin time (PT) , Partial Prothrombin Time (PTT) , International Normalized Ratio (INR) and d-Dimer were measured based on standards methods.

### 3.6. Data analysis

The demographic variables studied namely age and gender that were collected from the triage area. Data on clinical symptoms, hematological and coagulation parameters by inpatients with severe and critical COVID-19 were recorded. Data were checked and entered in Statistical Package for Social Science (SPSS) and Microsoft Excel. The data were subsequently visualized using tables, graphs and text. The results were described through calculations of medians, ranges, frequencies and percentages. Comparisons between qualitative variables were analyzed using Chi-squared test.

**Comment [d7]:** Which version of spss was used for the analysis?

## 1. RESULTS

### 3.1. Patients Characteristics

The background information of personal demographic and clinical data on the 49 patients that were admitted in COVID-19 isolation department , CTMID , AL Thawarah Public Hospital Authority in Hodeidah, Yemen and were summarized in Table 1.

**Comment [d8]:** The results should be written in past tense.

**Table 1.** Patients Characteristics of COVID-19

Variables	(n)	(%)	X <sup>2</sup>	p - value
<b>Gender</b>				
Male	40	81.16	19.62	0.00001*
Female	9	18.36		
Total	49	100		
<b>Age</b>				
<15	3	6.12	20.29	0.00044 *
15-29	2	4.10		
30 -49	11	22.44		
50-59	17	34.69		
60+	16	32.65		
Total	49	100		
<b>Clinical symptoms</b>				
• Difficulty breathing	42	85.7	NA	
• Fever	30	61.2		
• Cough	20	40.8		
• Joints pains	16	32.65		
• Sore throat	14	28.6		
• Headache	3	6.12		
<b>Total</b>	<b>49</b>	<b>100</b>		
<b>Severity illness</b>				
Severe cases	21	42.85	NA	
Critical cases	28	57.14		
Total	49	100		

**Comment [d9]:** The total sum is 99.52%, but not 100%. Check the numbers!

**Comment [d10]:** The total number is more above 100%. Some of the symptoms are repeated in one patient, so you should delete the total number below.

**Comment [d11]:** 99.99%.....not 100%

### 3.2. Hematological Characteristics

#### 3.2.1. Red Blood Cells and Hemoglobin

Anemia was reported in 50 % of cases (10.4 ± 3.5) and blood therapy was transfused into 10.20 % of cases in their treatment; however, the RBC don't change in response.

**Comment [d12]:** Firstly, the authors should describe below which Hb value the patient is anemic. Then, it is not clear if 10.4 ± 3.5 is the mean/average/median Hb..

**Comment [d13]:** It is not comprehensive if all patients did not respond to blood transfusion.

**Table 2.** Results of RBC count , Hb and PCV

Parameters	Mean ± SD (n = 49)	p value
RBC (×10 <sup>12</sup> /L )	4.34±0.95	p< 0.05
Median	4.45	
Rang	2.1-5.93	
Normal values	5.5±1.0	
Hb(g/dl )	10.84 ±2.16	p<0.05
Median	10.8	
Rang	6.4 -16.5	
Normal values	15.5 ± 2.5	
PCV ( % )	34.19 ±5.94	p< 0.05
Median	34.01	

**Comment [d14]:** It is not clear what shows the p-value in this table. Is this a comparison between RBC, Hb and PCV or between %, median, rang and referent values?

Rang	20.8 -46.3
Normal values	37.5 ± 47.5

### 3.2.2. White Blood Cells and Differential Count

The analysis revealed that 85.7% (n=42) patients had leukocytosis pretreatment with average count of WBC  $15.24 \pm 6.18 (\times 10^9/L)$ . The highest level of WBC was  $34 (\times 10^9/L)$ . On the other hand, the WBCs count, which had reached a peak of  $34 (\times 10^9/L)$  as maximum value.

Also, lymphocytes decreased (lymphopenia) with COVID -19 infection to 1 % with average (8.75±6.92%). In addition, neutrophils increased (neutrophilia) to 98 % with average (87.40±8.45%).

**Comment [d15]:** What about the absolute counts? Also it is not clear from what value is the decrease of Ly and the increase of the Neu.

**Table 3.** Results of WBC and Differential Count Parameters

Parameters	Mean ± SD (n = 49)	p value
WBC( $\times 10^9/L$ )	15.24±6.18	$p < 0.05$
Median	14.7	
Rang	5.6-34.0	
Normal values	3.5±7.5	
Neutrophil (%)	87.40 ± 8.45	$p < 0.05$
Median	90	
Rang	60-98	
Normal values	40-75	
Lymphocyte (%)	8.75 ± 6.92	$p < 0.05$
Median	6	
Rang	1-32	
Normal values	20-45	
Monocyte (%)	2.61 ± 2.32	$p > 0.05$
Median	3	
Rang	00-12	
Normal values	2-10	
Eosinophil (%)	1.02 ± 1.13	$p > 0.05$
Median	1	
Rang	0-5	
Normal values	1-6	
Basophil (%)	0.06±0.31	$p > 0.05$
Median	0	
Rang	0-2	
Normal values	0-1	

### 3.2.3. Platelets Count

Platelet count was found in normal range in 40/49 case (81.63 %) of COVID-19 patients. 3/49 (6.12 %) of patients indicated into severe thrombocytopenia (death). On the other hand , 6/49 of cases (12.24%) had increase in the platelets .


**Comment [d16]:** Define normal range

**Comment [d17]:** Define severe thrombocytopenia; what did you mean by death in brackets?

**Comment [d18]:** In what range? Above what value?

**Table 4. Results of Platelets Parameters**

Parameters	Mean ± SD (n = 49)	p value
Platelets ( $\times 10^3$ /ul)	313.55 ± 139.48	
Median	277	$p > 0.05$
Rang	75-450	
Normal values	150-400	



**Figure (1) :Abnormalities change percentage of hematological parameters**

### 3.4. Coagulation Parameters

The coagulation tests revealed **increase** in d-dimer levels ( $p < 0.05$ ) in severe and critical patients. On the other hand, the results showed **no change of referent value normal** in prothrombin time (PT) and partial thromboplastin (PTT) ( $p > 0.05$ ).

**Comment [d19]:** By what criteria were divided these 2 groups of patients? The statistically significant p-value by itself do not bring enough information... what was the data of comparing severe and critical patients?

**Table 5 Results of Coagulation Parameters**

Parameters	Mean ± SD (n = 49)	p value
d-dimer (mg/L )	3.5	$p < 0.05$
Median	4	
Rang	1.2 -10	
Normal values	0-0.5	
PT (Second)	11	$p > 0.05$
Median	10	
Rang	10-21	
Normal values	11-14	
PTT(Second)	28	$p > 0.05$
Median	32	
Rang	25-55	
Normal values	25-35	
INR	1.3	$p > 0.05$
Median	1.1	
Rang	1-1.8	
Normal values	Up to 1	

## 4.DISCUSSION

Hematologic manifestations of COVID-19 were initially reported in case series and descriptive studies of COVID-19 patients from China and other countries. Yang et al from China reported that infected with COVID-19 changed the levels of lymphocyte, neutrophil, LMR, and NLR in the blood, and these analyzing items were significantly different between the non-severe and severe groups. Furthermore, the dynamic changes of lymphocyte and NLR levels may help discriminate the severe group from the non-severe group [17,6]. Study in Pakistan was reported by Taj et al and concluded that leukocytosis, neutrophilia, elevated NLR, APTT, D-dimer, LDH and serum ferritin and CRP are associated with severity of covid-19 disease [18,7]. Javadi et al in Iran found that hemoglobin, WBCs, neutrophil, lymphocytes, and platelets count together with

**Comment [d20]:** First time mention abbreviations

**Comment [d21]:** Add citation

**Comment [d22]:** abbreviations

**Comment [d23]:** write the disease in the same way in the whole text (use big letters).

chest tomography score might be beneficial for expedition the diagnosis, assessment the severity of the disease, and outcome in the hospitalized cases, while CRP and LDH might be considered as the consequence of lung involvement[19,8]. Bhandary et al India reported to the known hematologic parameters implicated in COVID-19 illness such as NLR, eosinopenia and D-dimer, platelet parameters (MPV, PDW and PCT) can also be used as biomarkers that indicate the severity of the disease[20,9]. Szklanna et al in Ireland“ proof-of-concept study shows that a combination of activated partial thromboplastin time, white cell count-to-neutrophil ratio, and platelet count can predict subsequent severity of COVID-19 with high sensitivity and specificity at the time of the patient's hospital admission. These data, pending further validation, indicate that a decision tree model with hematological parameters could potentially form the basis for a rapid risk stratification tool that predicts COVID-19 severity in hospitalized patients[21,10]. Usul et al in Turkey concluded a statistically significant difference was found between the test groups regarding platelet, hemoglobin, leukocyte, neutrophil, NLR and SII values. Leukocyte, neutrophil, platelet count, NLR and SII values can be used in the diagnosis of COVID-19 [22,11].

**Comment [d24]:** Add Citation [20].

**Comment [d25]:** Add Citation [22].

**Comment [d26]:** Explain abbreviation

**Comment [d27]:** The forementioned markers might be used as predictors but for the diagnosis of COVID-19 is used only PCR.

**Comment [d28]:** Add citation

Other study by Suryawanshi et al in India concluded a significant decrease in lymphocytic counts was found among severe and critical patients. Hemoglobin level was found to demonstrate higher decrease among severe and critical patients. Platelet count was found in normal range in all COVID-19 patients [23,12]. Terpos et al in Greece reported that lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. NLR and peak PLR may also have prognostic value in determining severe cases. Elevated d-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID-19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted[24,13]. Rahi et al in USA reported that hematologic manifestations constitute a

**Comment [d29]:** Add citation

significant area of concern. Severe acute respiratory syndrome coronavirus 2 infects monocytes and endothelial cells leading to a complex downstream cascade, cytokine storm, and eventual intravascular thrombosis. Coronavirus disease 2019 causes lymphopenia, neutrophilia, and thrombocytopenia. Prophylactic anticoagulation is vital in patients with coronavirus disease 2019, as its effect on the coagulation system is associated with significant morbidity and mortality. The disease can cause both arterial and venous thromboses, especially pulmonary embolism and pulmonary microthrombi. A high index of suspicion is indispensable in recognizing these complications, and timely institution of therapeutic anticoagulation is vital in treating them. Virus-induced disseminated intravascular coagulation is uncommon but shares some similarities to sepsis-induced disseminated intravascular coagulation. Marked elevations in hematologic biomarkers such as lactate dehydrogenase, D-dimer, ferritin, and C-reactive protein are associated with worse outcomes. Understanding the pathophysiology and recognizing factors associated with poor prognosis are crucial in improving patient outcomes with coronavirus disease 2019[26,14].

Comment [d30]: Add citation

The available data suggest that neutrophilia is an expression of the cytokine storm and hyper inflammatory state which have an important pathogenetic role in COVID-19 and related infections such as SARS [12,18-20]. Cytoplasmic and nuclear morphological anomalies, from hyposegmented nuclei to apoptosis, have been described in circulating granulocytes at the time of hospital admission, Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes [3].

Comment [d31]: Abbreviation

Lymphopenia is a common finding in patients with COVID-19 infection and is believed to represent a defective immune response to the virus. In children, lymphopenia is much less common. In meta- analysis of 66 cases reported in the Chinese literature, Henry et al 17 identified lymphopenia in 3% of patients. This is in contrast to other similar viral infections, such as SARS, in which lymphopenia was a much more common finding in children [4].

Comment [d32]: Add citation

Neutrophils are the most characteristic cell type among the white blood cells and are an important component of the immune system. Regulated by mast cells, epithelial cells and macrophages, neutrophils also take part in inflammatory processes. The role of lymphocytes in both inflammation and infections is evident. Additionally, thrombocytes also have importance in the regulation of various inflammatory processes. While these parameters may be used as inflammatory markers by themselves, their ratios to one another may also be indicators of early inflammation . Circulating leukocytes respond to stress by increasing neutrophils and reducing lymphocytes; the ratio of these two parameters is also used as an inflammatory marker 4 [6].

Apart from RT-PCR testing for the organism, laboratory tests have not been assessed with regard to their sensitivity or specificity for the diagnosis of COVID-19, although their value as prognostic indicators has been established. Lymphopenia is a common finding in patients with COVID-19 infection and is believed to represent a defective immune response to the virus , leukocytosis in COVID-19-infected patients and appears to herald bacterial infection or superinfection , neutrophilia is due to bacterial superinfection, cytokine storm and thrombocytopenia is consumptive coagulopathy [26,15,3]. In addition , reduction of Hb is found from the study. These variations might be related to the case of infectious diseases, but low in nutritional values and the geographical location of Hodeidah city, Yemen [5].

Another potential application of data derived from the CBC would be to use formulas such as NLR, PLR , and MLR to act as surrogates to assess the extent of systemic inflammation [27,16] , AL Kamarany in Yemen have reported an increase in NLR in patients with severe COVID-19 infection [28,17]. In addition , SII is an easy-to-quantify parameter with high sensitivity and specificity to predict the clinical course of SARS CoV-2 infected patients. SII might be a valuable tool to improve the management of COVID-19 [29,18].

## Conclusion

**Comment [d33]:** Arrange in increasing order [3, 15, 26].

## CONSENT

As per international standards or university standards, Participants' written consent has been collected and preserved by the authors. The raw data are secured in the Center of Tropical Medicine and Infectious Diseases (CTMID), Al-Thawara Public Hospital Authority, Hodeidah, Yemen.

## ETHICAL APPROVAL

The studies involving human participants were reviewed and approved by the Ethics Committee of the Center for Tropical Medicine and Epidemiology Studies, Hodeidah University (CTMES – HU), Hodeidah, Yemen.

## REFERENCES

1. Saadi EAKD, Abdalnabi MA. Hematological changes associated with COVID-19 infection. *J Clin Lab Anal.* 2022 Jan;36(1):e24064. doi: 10.1002/jcla.24064. Epub 2021 Nov 16. PMID: 34783405; PMCID: PMC8646489.
2. Asghar M, Hussain N, Shoaib H, Kim M, Lynch TJ. Hematological characteristics of patients in coronavirus 19 infection: a systematic review and meta-analysis. *J Community Hosp Intern Med Perspect.* 2020 Oct 29;10(6):508-513. doi: 10.1080/20009666.2020.1808360. PMID: 33194119; PMCID: PMC7598996
3. Frater JL, Zini G, d'Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. *Int J Lab Hematol.* 2020 Jun;42 Suppl 1(Suppl 1):11-18. doi: 10.1111/ijlh.13229. PMID: 32311826; PMCID: PMC7264622.
4. Elkhalfi AME, Elderderi AY, Al Bataj IA, Tamomh AG, Alyami MM, Almakrami HA, Alofair MA, Almorish MA, Bashanfer S, Tabash MI, Idris HME, Ahmed DZ, Alhamidi AH, Mok PL. Hematological Findings among COVID-19 Patients Attending King Khalid Hospital at Najran, Kingdom of Saudi Arabia. *Biomed Res Int.* 2022 Feb 16;2022:4620037. doi: 10.1155/2022/4620037. PMID: 35224093; PMCID: PMC8865990.
5. Al-Sheibani, S., Osman Taha, S., Balkam, F., Dhafash, A., & Amood Al-Kamarany, M. Validation Hematological Analyzer for Assay of Erythrogram in Hodeidah City, Yemen. *Asian Hematology Research Journal*, 2018 March 1(1), 1-8. Retrieved from <https://journalahrj.com/index.php/AHRJ/article/view/13188>

6. Alahdal, M., Al-Shabi, J., Ogaili, M., Abdullah, Q. Y., Alghalibi, S., Jumaan, A. O., & AL-Kamarany, M. A. Detection of Dengue Fever Virus Serotype – 4 by using One-Step Real-Time RT-PCR in Hodeidah, Yemen. *Microbiology Research Journal International*, 2016 May ; 14(6), 1–7. <https://doi.org/10.9734/BMRJ/2016/24380>
7. Al-Areeqi, A., Alghalibi, S., Yusuf, Q., Al-Masrafi, I., & Al-Kamarany, M. A. Epidemiological Characteristic of Malaria Coinfected with Dengue Fever in Hodeidah, Yemen. *International Journal of TROPICAL DISEASE & Health*, 2020 February ; 40(3), 1–10. <https://doi.org/10.9734/ijtdh/2019/v40i330230>
8. Yusuf QA, Ogaili M, Alahdal M, Amood Al Kamarany M. Dengue fever infection in Hodeidah, Yemen risk factors and socioeconomic indicators. *British Biomed Cal Bullieten*. 2015;3(1):58–65.
9. Yusuf, Q., Al-Masrafi, I., Al-Mahbashi, A., Al-Areeqi, A., Al-Kamarany, M. A., & Khan, A. S. (2019). First Evidence of West Nile Virus in Hodeidah, Yemen: Clinical and Epidemiological Characteristics. *International Journal of TROPICAL DISEASE & Health*, 38(4), 1-9. <https://doi.org/10.9734/ijtdh/2019/v38i430190>  
<https://journalijtdh.com/index.php/IJTDH/article/view/30190>
10. Al Kamarany , M. A., Majam , A., Suhail , K., Zuhairy , A., &Alabsi , E. (2023). Coronavirus Disease 2019 – Dengue Fever Coinfection: A Case Report. *International Journal of Pathogen Research*, 12(4), 27–32. <https://doi.org/10.9734/ijpr/2023/v12i4234>
11. AL-Kamarany MA, Suhail KA, Majam AS, AbdulabariAlabsi E, et al. Epidemiological and clinical features of COVID-19 in Hodeidah, Yemen. *International Journal of Tropical Disease & Health*. 2021;42(21): 28–40. Available:<https://doi.org/10.9734/ijtdh/2021/v42i2130550>
12. Suhail FA, Al Kamarany MA. Radiological features of COVID-19 patients in Hodeidah, Yemen. *Asian Journal of Research in Infectious Diseases*. 2021;8(4):117-127. Available:<https://doi.org/10.9734/ajrid/2021/v8i430256>
13. Majam A, AL KamaranyAmood M. COVID -19 and dengue coinfection, predication for increasing the mortality rate: Case report. *The First Scientific Annual Conference of AL Thawara Public General Authority*; 2021
14. AL-Kamarany, M. A., Suhail, K. A., Majam, A. S., AbdulabariAlabsi, E., HamoudDowbalah, M., & Mohammed Zohairy, A. (2021). Epidemiological and Clinical

- Features of COVID-19 in Hodeidah, Yemen. *International Journal of TROPICAL DISEASE & Health*, 42(21), 28–40. <https://doi.org/10.9734/ijt dh/2021/v42i2130550>
15. AL Kamarany , M. A., Abdulkarim , T., & Nasser , M. (2023). Biomolecular Features of COVID-19 in Hodeidah, Yemen. *Asian Journal of Biochemistry, Genetics and Molecular Biology*, 14(3), 29–38. Available:<https://doi.org/10.9734/ajbgmb/2023/v14i3317>
  16. Al-Kamarany, M. A., & Abdulkarim , T. (2023). Immunological Features of COVID-19 in Hodeidah, Yemen. *Asian Journal of Immunology*, 6(1), 76–84. Retrieved from <https://journalaji.com/index.php/AJI/article/view/97>
  17. Yang H , Xu Y, Li Z, Yan L, Wang J, Liao P. The Clinical Implication of Dynamic Hematological Parameters in COVID-19: A Retrospective Study in Chongqing, China. *Back to Journals » International Journal of General Medicine » Volume 14 30 July 2021* Volume 2021:14 Pages 4073—4080. DOI <https://doi.org/10.2147/IJGM.S321292>
  18. Taj S, Kashif A, Arzinda Fatima S, Imran S, Lone A, Ahmed Q. Role of hematological parameters in the stratification of COVID-19 disease severity. *Ann Med Surg (Lond)*. 2021 Feb;62:68-72. doi: 10.1016/j.amsu.2020.12.035. Epub 2021 Jan 8. PMID: 33437468; PMCID: PMC7792501.
  19. Javadi A, Dabiri S, Meymandi MS, HashemiBahremani M, Soleimantabar H, Dabiri B, Vosough H, Gheidi Sharan M, Sedaghati F. Changes of Routine Hematological Parameters in COVID-19 Patients: Correlation with Imaging Findings, RT-PCR and Outcome. *Iran J Pathol*. 2022 Winter;17(1):37-47. doi: 10.30699/IJP.2021.533645.2675. Epub 2021 Dec 15. PMID: 35096087; PMCID: PMC8794564.
  20. Bhandary, C. P.; Agarkar, P. L.; Manivannan, P.; Kar, R.; Basu, D.. Hematological parameters in covid-19 illness: Emphasis on platelet indices as a marker of severity of disease. *Indian Journal of Hematology and Blood Transfusion* ; 36(1 SUPPL):S128, 2020, ArtigoemInglês | EMBASE | ID: covidwho-1092783
  21. Szklanna PB, Altaie H, Comer SP, Cullivan S, Kelliher S, Weiss L, Curran J, Dowling E, O'Reilly KMA, Cotter AG, Marsh B, Gaine S, Power N, Lennon Á, McCullagh B, NíÁinle F, Kevane B and Maguire PB (2021) Routine Hematological Parameters May Be Predictors of COVID-19 Severity. *Front. Med.* 8:682843. doi: 10.3389/fmed.2021.682843

22. Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19 patients in the emergency room. *Biomark Med.* 2020 Sep;14(13):1207-1215. doi: 10.2217/bmm-2020-0317. Epub 2020 Jul 21. PMID: 32692248; PMCID: PMC7372996.
23. Suryawanshi, ShekharYashwant; Priya, Shrishtee; Sinha, SandarbSaumya; Soni, Srinath; Haidry, Naqoosh; Verma, Shilpi; Singh, Supriya,. Dynamic profile and clinical implications of hematological and immunological parameters in COVID-19 patients. A retrospective study. *Journal of Family Medicine and Primary Care: July 2021 - Volume 10 - Issue 7 - p 2518-2523* doi: 10.4103/jfmpe.jfmpe\_2400\_20
24. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. *Am J Hematol.* 2020 Jul;95(7):834-847. doi: 10.1002/ajh.25829. Epub 2020 May 23. PMID: 32282949; PMCID: PMC7262337.
25. Rahi MS, Jindal V, Reyes SP, Gunasekaran K, Gupta R, Jaiyesimi I. Hematologic disorders associated with COVID-19: a review. *Ann Hematol.* 2021 Feb;100(2):309-320. doi: 10.1007/s00277-020-04366-y. Epub 2021 Jan 7. PMID: 33415422; PMCID: PMC7789889.
26. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. *Clin Chem Lab Med.* 2020 Mar 19. pii: /j/cclm.ahead-of-print/cclm-2020-0240/cclm-2020-0240.xml. <https://doi.org/10.1515/cclm-2020-0240>. [Epub ahead of print].
27. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin Infect Dis.* 2020. <https://doi.org/10.1093/cid/ciaa248>. [Epub ahead of print].
28. AL KamaranyAmood M. Validation of Neutrophils - Lymphocytes Ratio for Monitoring of Therapeutic Efficacy of COVID -19 in Hodeidah , Yemen. *The second conference for laboratory medicine . 20 – 23 Mar 2021, 43-44 .*
29. Muhammad S, Fischer I, Naderi S, Faghieh Jouibari M, Abdolreza S, Karimialavijeh E, Aslzadeh S, Mashayekhi M, Zojaji M, Kahlert UD, Hänggi D. Systemic Inflammatory Index Is a Novel Predictor of Intubation Requirement and Mortality after SARS-CoV-2 Infection. *Pathogens.* 2021 Jan 11;10(1):58. doi: 10.3390/pathogens10010058. PMID: 33440649; PMCID: PMC7827801.

UNDER PEER REVIEW

